1. Volume 8, Issue 3, Pages 393-400 (March 2011)
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) 
Jonathan P. Piccini, MD, MHS, Sana M. Al-Khatib, MD, MHS, Anne S. Hellkamp, MS, Kevin J. Anstrom, PhD, Jeanne E. Poole, MD, Daniel B. Mark, MD, MPH, Kerry L. Lee, PhD, Gust H. Bardy, MD 
Heart Rhythm 
Volume 8, Issue 3, Pages (March 2011)
DOI: /j.hrthm
Copyright © 2011 Heart Rhythm Society Terms and Conditions

2. Figure 1
Distribution of time between myocardial infarction and randomization/implantation. Each bar represents 3-month intervals.
Heart Rhythm 2011 8, DOI: ( /j.hrthm )
Copyright © 2011 Heart Rhythm Society Terms and Conditions

3. Figure 2
Kaplan-Meier event rates in patients treated with an ICD vs. placebo according to time from MI to implantation/randomization (tertiles) for (A) all-cause mortality and (B) sudden cardiac death.
Heart Rhythm 2011 8, DOI: ( /j.hrthm )
Copyright © 2011 Heart Rhythm Society Terms and Conditions

4. Figure 3
Kaplan-Meier rates of appropriate ICD therapy according to the time from myocardial infarction to implantation/randomization.
Heart Rhythm 2011 8, DOI: ( /j.hrthm )
Copyright © 2011 Heart Rhythm Society Terms and Conditions